EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR Cancers and to Metastatic Cervical Cancer with PD-L1 CPS ≥1
New indications concern the treatment of patients with MSI-H or dMMR advanced colorectal, endometrial, gastric, small intestine, or biliary cancers, and PD-L1-positive metastatic cervical cancer